Around the Journal

  • New Trump travel ban a detriment to biotech

    Like its predecessor, the new Executive Order is deeply detrimental to America's efforts to develop important new medicines to address serious unmet human needs. In addition it remains just as inimical to the fundamental values on which our great nation was founded.

  • Focus: RNA-based therapies

    To highlight advances in delivery technologies and improved chemistry that have propelled the clinical advancement of RNA-based therapies (antisense, siRNAs, aptamers, microRNA mimics/anti-miRs and synthetic mRNA), Nature Biotechnology and Nature Reviews Drug Discovery present a joint focus on RNA-based therapies.

  • US immigration order strikes against biotech

    We the undersigned, founders and leaders of biotech companies, write to express our deep concern and opposition to the executive order signed by President Donald Trump on January 27, 2017, barring the entry of citizens from seven countries into the United States.